Analysts Change Price Targets on These 2 Healthcare Companies As End of Year Approaches

Wall Street stock analysts reiterated ratings in the Healthcare sector for the week ending December 23rd, 2011 for these 2 companies:

AtriCure (NASDAQ:ATRC): Kaufman Bros reiterated its rating of Buy for this company and changed its price target from $14 to $16 on Dec 21st. The shares recently traded at $11.72, down $0.06, or 0.51% since the analyst’s rating. About the company: AtriCure, Inc. develops, manufactures, and sells surgical devices designed to create precise lesions in soft tissues. The Company’s bipolar ablation system is used by cardiothoracic surgeons as a standard treatment alternative to create lesions in heart tissue to block the abnormal electrical impulses that cause atrial fibrillation. Get the most recent company news and stock data here >>

C.R. Bard (NYSE:BCR): Mizuho reiterated its rating of Neutral for this company and changed its price target from $80 to $75 on Dec 21st. The shares recently traded at $85.12, up $1.08, or 1.29% since the analyst’s rating. About the company: C. R. Bard, Inc. designs, manufactures, packages, distributes, and sells medical, surgical, diagnostic, and patient care devices. The Company sells a broad range of products worldwide to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities. Bard markets vascular, urological, oncological, and surgical specialties products. Get the most recent company news and stock data here >>

(Note: Selected financial data are sourced from Briefing.com via the Wall St. Journal. All data are assumed to be accurate.)

Advantage: Check out our interactive stock charts, fundamentals, Twitter stream, and more >>

Improve Your 2011 Financial Health: Join the winning team of stock pickers with Wall St. Cheat Sheet’s acclaimed premium newsletter>>